Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytoreductive prostatectomy plus ADT + darolutamide + docetaxel in new oligometastatic hormone-sensitive prostate cancer (Phase II)
ChiCTR2600121389Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide and docetaxel in prostate cancer (PCa), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Rate of non-progression to castration-resistant prostate cancer (CRPC) at 1 year. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
darolutamidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2600121389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121389.